CorTec’s brain-computer interface (BCI) has obtained breakthrough device designation from the US Food and Drug Administration (FDA) for use in stroke rehabilitation.
Under development for brain-based communication and neural recording, the breakthrough designation covers the Germany company’s implantable BCI for the provision of direct cortical electrical stimulation, on the basis of recorded brain signals, to support motor recovery in people living with chronic stroke-related impairments.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to CorTec, it is the first BCI developer to be granted an FDA breakthrough designation for such an indication.
Combining neural signal recording with adaptive stimulation in a closed-loop configuration, CorTec’s system is currently being evaluated in an investigational device exemption (IDE) study at the University of Washington, representing the first clinical investigation of a fully implantable BCI system for stroke rehabilitation patients.
Since obtaining the FDA IDE in May 2024, two patients have been implanted with Brain Interchange, with the second successful implantation completed in February 2026. Beyond stroke, the BCI is also being evaluated for epilepsy, with further indications including paralysis and depression under development.
CorTec CEO, Dr Frank Desiere commented: “Achieving this designation is a defining milestone for CorTec and underscores the potential of our Brain Interchange system to address the significant unmet need in stroke rehabilitation.”
Highlighting that long-term data published in Nature Scientific Data has demonstrated Brain Interchange’s signal stability for 500 days, Desiere added that the breakthrough designation provides CorTec with “strong momentum” as it plans to advance its system towards larger clinical trials.
Mara Assis, head of regulatory affairs and quality management at CorTec, commented. “Our regulatory strategy has followed a stepwise approach, from prior device clearance to IDE approval and successful human implantations. This designation will help accelerate planning of clinical trials and support the next regulatory milestones.”
According to GlobalData analysis, the global neurology devices market is projected to reach a valuation above $25bn in 2034.
Implanted in brain tissue, BCI chips are designed to translate brain signals into actionable commands. The market is current on a rapid advancement course across multiple indications, including the restoration of movement ‘through thoughts alone’ with Neuralink’s BCIs, along with functions including vision restoration with ReVision Implant’s Occular BCI.
According to GlobalData analysts, BCIs are on the verge of commercialisation, with initial market launches anticipated in 2030.
